Compare AstraZeneca plc (AZN) vs Altria Group Inc (MO) Price & Performance

AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).

The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.

Altria Group (MO) trades at $68.35, up 0.89% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains strong profitability with 39% net income margin and $6.95B net income for 2025, though revenue declined slightly to $20.14B. Recent earnings show alternating beats and misses, with Q3 2026 results pending. Analyst consensus remains bullish with 61.5% buy ratings and $71.50 price target, while the stock offers a 6.3% dividend yield with 56 consecutive annual increases expected.

MO presents value opportunity with 14.4x P/E ratio and strong cash flow generation, but faces headwinds from cigarette volume declines and regulatory pressures. The smoke-free product transition shows progress but remains early stage. Current price near support at $67 suggests limited downside, while analyst targets indicate 4.6% upside potential. Key risks include litigation exposure and slower-than-expected diversification from traditional tobacco products.